175 results about "High-Fat Diets" patented technology

The present invention relates to methods for prevention and / or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

The invention discloses a preparation method and application of spirulina whole active substances. Spirulina is used as a raw material. The spirulina whole active substances are extracted and prepared by the method of performing extraction with solvents of different polarities (from small to large), performing enzymolysis with compound proteinases and the like, and are prepared through the following steps of firstly performing extraction with 85-95wt% ethanol, then performing extraction with 55-65wt% ethanol, then performing water extraction, finally performing enzymolysis on water extraction residues, then performing centrifuging, performing filtration, performing decompression, performing concentration, and performing drying so as to obtain a spirulina 85-95wt% ethanol extract, a spirulina 55-65wt% ethanol extract, a spirulina water extract and a spirulina zymolyte, namely the spirulina whole active substances. Pharmacodynamics experiments verify that the whole active substances can significantly improve lipid metabolism disorder induced by high fat diet, and specifically, can significantly reduce the level of total cholesterol (TC), the level of triglyceride (TG) and the level of low density lipoprotein cholesterol (LDL-C) in serum.

The invention discloses bifidobacterium pseudocatenulatum CCFM1046, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1046 can tolerate gastrointestinal environments in human bodies, the rising of hepatic triglyceride content of metabolic syndrome mice caused by high-fat diet can be significantly improved; the weight increasing of the metabolic syndrome mice can be alleviated; the abnormal fasting blood glucose and oral glucose tolerance of the metabolic syndrome mice can be significantly improvedas well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be enhanced; the rising of low-density lipoprotein cholesterol in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteus genus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1046 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1046 can have very wide application prospects.

α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using AHSG antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and / or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.

The invention belongs to the field of pharmacy, and relates to applications of leonurine in preparation of medicines used for treating atherosclerosis. Leonurine possesses a structure represented by formula (I). It is shown by results of experiments on a rabbit model with high fat diet induced atherosclerosis that, leonurine possesses anti-inflammatory activity and antioxidant activity, so that leonurine is capable of increasing the content of high-density lipoprotein, reducing the content of total cholesterol, reducing mean blood flow velocity of arteries, improving blood flowing states, protecting the integrity of blood vessel endothelium, and reducing deposition of lipid in blood vessels and generation of macrophage, and can be used for treating atherosclerosis.

The invention provides application of an aqueous fructus amomi extract and olatile oil in preparation of a drug for losing weight and reducing blood fat. Fructus amomi is smashed, soaked and decocted to obtain an aqueous extract, or the fructus amomi (Amomun villosum Lour) is smashed and soaked, and the volatile oil is extracted and collected through a steam distillation method. The obtained anti-obesity drug adopts raw materials with homology of medicine and food, has the effects of controlling the obesity induced by high fat diet, relieving hyperlipidaemia in an obesity state, inhibiting the high serum endotoxin state in the obesity state and inhibiting pancreatic lipase and can well achieve the purpose of healthily reducing the fat.

The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition. When the present compositions are administrated into genetically obese mice or high fat diet-induced obese mice, the present compositions reduced body weight, body fat and gonadal fat, and reduce blood cholesterol level and obesity-related blood glucose level. Also, the present compositions suppress hypertrophy of adipocytes, and inhibit the accumulation of lipid in the liver by reducing the size and number of lipid vacuoles. Furthermore, in human clinial trial the present compositions show that body weight, PIBW, body fat, especially visceral fat, apolipoprotin B concentration, ratio of total cholesterol / HDL cholesterol and ratio of LDL cholesterol / HDL cholesterol are significantly decreased, and atherogenic index is improved and muscle mass is increased. Thus, the present compositions can be usefully applied as antiobesity composition for reduction of body weight and suppression of abdominal fat, particularly, visceral fat.

The invention discloses lactobacillus rhamnosus with a fatty liver disease inhibiting function and application thereof. A strain, L. rhamnosus NCU2217, is collected, with the collection number CGMCC NO15573, in the China General Microbiological Culture Collection Center on April 9, 2018. The address of the China General Microbiological Culture Collection Center (referred to as CGMCC) is Instituteof Microbiology, Chinses Academy of Sciences, No. 3, No. 1 Courtyard, Beichen West Road, Chaoyang District, Beijing, China. The L. rhamnosus and food prepared therefrom have the effects of inhibitingliver function damage, reducing liver fat accumulation, improving the microstructures of fatty livers and promoting liver damage repair on non-alcoholic fatty liver diseases induced by high-fat diet.

The present invention discloses a novel Bifidobacterium DD98 having a 16SrDNA nucleotide sequence shown in SEQ ID No: 1. Further, the Bifidobacterium is preserved in the General Microbial Culture Collection Management Center of China, and a preservation number is CGMCC No. 16573. The Bifidobacterium DD98 of the invention can tolerate higher selenium pressure, can be used for selenium-enriched culture, and has good intestinal colonization ability, and the extracted water-soluble protein has intestinal protection function. The Bifidobacterium DD98 of the invention can alleviate liver damage caused by a high-fat diet and alcohol, and has the protective effect on the liver.

The invention discloses new application of axitinib. Axitinib can be used for preparing medicine for promoting white fat cell browning and used for preventing and treating obesity and diseases related to obesity. The medicine can promote primary white fat cell browning in vitro, thereby enhancing expression of brown fat cell marker gene uncoupling protein 1 (UCP1), and can promote the increase of beige fat cells in white fat tissue of groin and the increase of expression of UCP1; the medicine can resist obesity and insulin insensitivity caused by high-fat diet and has an effect on treating fatty livers.

The present invention provides a prophylactic or therapeutic agent for a hepatic disease, containing AIM or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same, a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an0 animal obtained by loading a non-human mammal deficient in AIM expression with a high fat diet and the like.

The invention discloses application of recombinant human cytoglobin (rhCYGB) in preparation of drugs treating hyperlipidemia and atherosclerosis. A hyperlipidemia rat model and an atherosclerosis rat model are respectively established by the inventor, and subcutaneous injection of rhCYGB is carried out for treatment. Experimental results show that the rhCYGB drug is non-toxic, compared with a model control group, the rhCYGB treatment group has significant improvement, the four items of blood lipid test are significantly decreased than those of a model group, and the four items of blood lipid test of a polysaccharide sulfate treatment group are significantly higher than normal, thus rhCYGB has better efficacy than polysaccharide sulfate in treatment of hyperlipidemia caused by high fat diet. In the atherosclerosis rat model, compared with the model group, the four items of blood lipid test of the treatment group are also significantly reduced, and atherosclerotic plaques also obviously decreased. Therefore, treatment of hyperlipidemia and atherosclerosis by the recombinant human cytoglobin has the advantages of low toxicity, safety and effectiveness.

The invention provides an application of alpha-mangostin for prevention and treatment of diabetes mellitus. Alpha-mangostin can be used for decreasing blood glucose of diabetics, increasing glucose tolerance and improving symptoms of polydipsia, polyuria, polyphagia, emaciation and thirsty of the diabetics, can also be used for lowering high-fat-diet-induced obesity mouse total cholesterol content, has a cholesterol lowering effect, is capable of improving abnormality of the high-fat-diet-induced mouse glucose tolerance, and has functions of preventing and delaying obese patients from getting diabetes mellitus.

The invention provides new compositions or combinations thereof for the treatment of cancer. More specifically, the invention provides compositions or combinations thereof for cancer treatment including a high-fat diet. Specifically, the high-fat diet is characterized by having approximately 120 g / day or more, or approximately 70% or more of the total daily energy, from fat, based on a real body weight of 50 kg. The diet is preferably a carbohydrate-restricted high-fat diet, and more preferably provided by a ketone formula and / or MCT oil. The dietary therapy by a high-fat diet of the present invention is provided along with surgical treatment, chemotherapy or radiation therapy, or combinations thereof.

The invention discloses lactobacillus rhamnosus capable of intervening in metabolic syndrome and an application, in particular to a strain capable of intervening in metabolic syndrome. The lactobacillus rhamnosus can be added into various healthy foods and health-care foods, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus CCFM1146 as well as a composition, a fermented food, an application, a microbial agent and a microbial agent preparation method thereof. According to the lactobacillus rhamnosus CCFM1146, the metabolic syndrome caused by high-fat diet are remarkably improved; the blood glucose, glucose tolerance and insulin resistance index level of metabolic syndrome mice are remarkably improved; the abundance of microorganisms in intestinal tracts is remarkably improved, and a colon barrier structure is maintained; and the level of proinflammatory factor IL-6 in liver is remarkably improved. The lactobacillus rhamnosus CCFM1146 isused for preparing pharmaceutical compositions and the fermented food for relieving the metabolic syndrome, non-alcoholic fatty liver disease, diabetes and other diseases, and has a very wide application prospect.

The present invention relates to an extract of mixed herb medicine, and a pharmaceutical composition for the prevention and treatment of obesity containing the extract as an effective ingredient or health food containing the same, more precisely, an extract of mixed herb medicine extracted from the mixture of cassia seeds (Cassia obtusifolia L.), green tea (Thea sinensis L.), eucommia bark (Eucommia ulmoides Oliver), garlic (Allium sativum var. pekinense), hawthorn (Crataegus Pinnatifida Bunge), fresh pine needle (Pinus densiflora Siebold et Zuccarini) and wormwood (Artemisia capillaris Thunberg) using water or aqueous alcohol solution, a pharmaceutical composition for the prevention and treatment of obesity containing the above extract and a fermented extract extracted after adding rice, malt and yeast to the above mixture, or health food containing the same. The extract of the present invention can be effectively used for the prevention and the treatment of obesity by inhibiting weight gain by high-fat diet, lowering blood cholesterol and decreasing neutral fat (triglyceride).

The invention discloses bifidobacterium pseudocatenulatum CCFM1045, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1045 can tolerate gastrointestinal environments in human bodies, the abnormity of metabolic syndrome mouse serum liver function indexes ALT and AST caused by high-fat diet can be significantly improved; the abnormal oral glucose tolerance of metabolic syndrome mice can be significantly improved as well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be decreased; the rising of triglycerides and total cholesterol content in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteusgenus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1045 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1045 can have very wide application prospects.

The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.

The invention discloses a Potentilla viscosa Donn extract and application thereof. The extract is a water extract of Potentilla viscosa Donn, a 30-100% ethanol extract product or a 30-100% methanol extract. The extract has a remarkable effect of improving high-fat diet induced fatty liver and liver injury and has an obvious effect of reducing blood sugar. It shows that the extract has a remarkableeffect of treating diabetes. There is no report related to therapeutic effect of Potentilla viscosa Donn on fatty liver and diabetes at present. Experimental data show that the high-dose Potentilla viscosa Donn extract group has better hypoglycemic effect than a metformin group and the product shows a good application prospect.

The invention discloses a strain of lactobacillus fermentum KP101 and application thereof in preparing fermented yogurt and probiotic solid beverages. The preservation number of the lactobacillus fermentum KP101 is CCTCC No. 2019085. The lactobacillus fermentum KP101 has good acid stress resistance, cholate stress resistance and oxidative stress resistance, can resist pathogenic infection, regulate metabolic disturbance, regulate hyperlipidemia and the like, and also can reduce fat and reduce weight. Animal experiments show that the increase of TG and LDL-c in serum caused by high fat diet canbe effectively reduced by 50.5% and 67.0% respectively; the level of HDL-C in liver can be significantly improved by 78.9%; the contents of TC, TG and LDL-C in liver can be reduced by 36.2%, 64.6% and 42.8% respectively; a significant fat reducing effect is also achieved, and the perirenal fat reduction coefficient and the abdominal fat reduction coefficient are 97.2% and 95.5% respectively.

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from Akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical / food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet. In addition, in the present invention, a fermented food itself, prepared by adding Akkermansia muciniphila, can be used for the purpose of preventing or alleviating a metabolic disease occurring or exacerbated due to a high fat diet.

The invention discloses an application of a polypeptide specifically bingd to TRB3 or a derivative of the polypeptide in the preparation of medicines for treating and / or preventing metabolic syndrome. The amino acid sequence of the polypeptide is represented by anyone of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; and the derivative of the polypeptide is a chimeric peptide formed by connecting the polypeptide with a cell penetrating peptide and / or a medicinal composition formed by cooperating the polypeptide with a medicinal assistant. The polypeptide or the polypeptide derivative can specifically bind to the TRB3 in order to block out interaction between the TRB3 and a P62 protein, and the peptide derivatives Pep2-A1, Pep2-A2 and Pep3-A3 can be used to treat high fat diet induced mouse metabolic syndrome.

The present invention relates to a fusion protein consisting of a C2 domain and an Akt protein fragment, particularly the fragment consisting of the amino acid residues ranging from the 111th to the 480th amino acids from the N-terminus of the Akt protein, and a use of the said fusion protein. More specifically, the fusion protein of the present invention increases the Akt protein activity even under the condition of high calcium concentration, reduces body weight and fat in an animal model treated with a high fat diet infected with adenovirus containing the fusion protein above, improves insulin resistance and improves fatty liver, so that the fusion protein comprising the C2 domain and the fragment consisting of the amino acid residues ranging from the 111th to 480th amino acids from the N-terminus of Akt protein can be effectively used for the treatment of metabolic disease.

There is provided a composition for preventing and treating obesity including high water-soluble β-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble β-cyclodextrin derivatives, especially, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner.

The invention discloses application of an alcohol extract of viburnum sargentii koehne to preparation of medicines for treating AS (atherosclerosis) diseases. By taking C57BL / 6J mice as blank control and taking a simvastatin medicated group as positive control, observation of influences of the viburnum sargentii koehne on AS and exploration of corresponding mechanisms are carried out after a high fat diet-induced apoE<- / -> mouse AS model is intragastrically given with the alcohol extract of the viburnum sargentii koehne for 12 weeks. According to results, the alcohol extract of the viburnum sargentii koehne evidently lowers the level of lipids in serum, inhibits oxidative stress and inflammatory reaction, decelerates formation of atheromatous plaques and lipid accumulation on arterial walls of the high fat diet-induced apoE<- / -> mouse and inhibits AS occurrence and development. By application of the alcohol extract of the viburnum sargentii koehne to preparation of the medicines for treating the AS diseases, not only is a novel usage of the alcohol extract of the viburnum sargentii koehne is developed, but also a novel approach of AS treatment is provided.

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol / low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a preparation method and application of a herba ardisiae japonicae alcohol extract. The preparation method comprises the following steps: after drying and crushing a herba ardisiae japonicae medicinal material at low temperature, weighing 0.1g of the crushed herba ardisiae japonicae medicinal material, and adding 0.1mL of methanol; after carrying out vortex oscillation, carrying out ultrasonic treatment and cooling; then weighing the weight, and supplementing the reduced weight with the methanol; uniformly shaking and filtering; taking subsequent filtrate and preserving for later use; weighing a bergenin reference substance, and adding the methanol to prepare a solution; determining the content of bergenin in the herba ardisiae japonicae alcohol extract by adopting an ultra-high performance liquid chromatography. According to the preparation method and the application of the herba ardisiae japonicae alcohol extract, the content of the bergenin in the herba ardisiae japonicae alcohol extract is 9.88mg / g and accords with quality standards; herba ardisiae japonicae can be used for reducing the quantity of lipid droplets in ST-2 and C3H10 cells which are obtained by inducing adipogenesis differentiation, and for inhibiting mRNA expression of adipogenesis differentiation characterization genes PPARgamma, C / EBPalpha and aP2; interventional treatment of the herba ardisiae japonicae can be used for effectively reducing the weight of C57BL / 6 mice fed by high fat diet.

The invention provides a composition for treating type 2 diabetes. The composition for treating the type 2 diabetes is composed of at least one of glycine and valine and pharmaceutical adjuncts. Studyof the invention finds that by supplementing a certain amount of glycine or valine, high fat diet-induced type 2 diabetes can be greatly alleviated and improved, and hyperglycemia caused by high fatdiet can be alleviated, and a long-term blood glucose lowering effect is achieved; and the study also finds that mechanisms of the glycine and valine for treating the type 2 diabetes are similar, blood glucose is respectively lowered by regulating secretion of two hormones, namely glucagon and insulin, in vivo, and glucose content in blood becomes more normal, so that glucose tolerance of an organism becomes more normal.